JP2017533707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533707A5 JP2017533707A5 JP2017523289A JP2017523289A JP2017533707A5 JP 2017533707 A5 JP2017533707 A5 JP 2017533707A5 JP 2017523289 A JP2017523289 A JP 2017523289A JP 2017523289 A JP2017523289 A JP 2017523289A JP 2017533707 A5 JP2017533707 A5 JP 2017533707A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- cancer
- disease
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 43
- 108010052285 Membrane Proteins Proteins 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 28
- 108020004999 messenger RNA Proteins 0.000 claims description 28
- 102000018697 Membrane Proteins Human genes 0.000 claims description 25
- 230000003834 intracellular effect Effects 0.000 claims description 21
- 238000004520 electroporation Methods 0.000 claims description 17
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 14
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 4
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- -1 CD86 Proteins 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 206010043207 temporal arteritis Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 102000002627 4-1BB Ligand Human genes 0.000 claims description 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100035793 CD83 antigen Human genes 0.000 claims description 2
- 201000002829 CREST Syndrome Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102100030704 Interleukin-21 Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims description 2
- 238000009172 cell transfer therapy Methods 0.000 claims description 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000003027 ear inner Anatomy 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001994 temporal artery Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073268P | 2014-10-31 | 2014-10-31 | |
| US62/073,268 | 2014-10-31 | ||
| PCT/US2015/058228 WO2016069993A1 (en) | 2014-10-31 | 2015-10-30 | Compositions and methods of stimulating and expanding t cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533707A JP2017533707A (ja) | 2017-11-16 |
| JP2017533707A5 true JP2017533707A5 (OSRAM) | 2018-12-06 |
| JP6884697B2 JP6884697B2 (ja) | 2021-06-09 |
Family
ID=55858377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523289A Active JP6884697B2 (ja) | 2014-10-31 | 2015-10-30 | Ｔ細胞を刺激および拡大する組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11471487B2 (OSRAM) |
| EP (1) | EP3217989B1 (OSRAM) |
| JP (1) | JP6884697B2 (OSRAM) |
| KR (2) | KR102583138B1 (OSRAM) |
| CN (1) | CN107106609A (OSRAM) |
| AU (1) | AU2015339106B2 (OSRAM) |
| CA (1) | CA2966035A1 (OSRAM) |
| ES (1) | ES2910227T3 (OSRAM) |
| WO (1) | WO2016069993A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3564265A4 (en) | 2016-12-30 | 2021-02-17 | Cytocares (Shanghai) Inc. | Trifunctional molecule and application thereof |
| US12234479B2 (en) | 2016-12-30 | 2025-02-25 | Cytocares (Shanghai) Inc. | Bifunctional molecule and use thereof |
| CN110662834B (zh) * | 2017-05-26 | 2023-09-12 | Gc细胞治疗 | 使用转化的t细胞培养自然杀伤细胞的方法 |
| KR20250111214A (ko) | 2017-09-01 | 2025-07-22 | 론차 콜로그네 게엠베하 | 엔드-투-엔드 세포 요법의 자동화 |
| US12460174B2 (en) | 2018-09-28 | 2025-11-04 | Octane Biotech Inc. | Magnetic separation |
| EP3892721A4 (en) | 2018-11-14 | 2022-08-31 | GC Cell Corporation | METHOD FOR CULTIVATING NATURAL KILLER CELLS DERIVED FROM UMBILICAL CORD BLOOD USING TRANSFORMED T LYMPHOCYTES |
| CA3123314A1 (en) | 2018-12-21 | 2020-06-25 | Octane Biotech Inc. | Carousel for modular biologic production units |
| CA3123449A1 (en) | 2018-12-21 | 2020-06-25 | Lonza Walkersville, Inc. | Automated production of viral vectors |
| CN113498432A (zh) | 2019-02-08 | 2021-10-12 | 隆萨沃克斯维尔股份有限公司 | 用于自动化生物反应器的细胞浓缩方法和装置 |
| IL292409A (en) | 2019-10-24 | 2022-06-01 | Octane Biotech Inc | A cell culture chamber with enhanced cell contact surfaces |
| KR20220097457A (ko) | 2019-11-11 | 2022-07-07 | 론자 워커스빌 아이엔씨. | 자동화된 세포 처리를 위한 품질 관리 방법 |
| AU2020394427A1 (en) * | 2019-11-27 | 2022-07-14 | The Trustees Of The University Of Pennsylvania | Anti-CD3 scFv and cytokine producing artificial antigen presenting cells |
| CN114606263B (zh) * | 2022-05-11 | 2022-09-06 | 上海优替济生生物医药有限公司 | 分离的核酸分子及其用途 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| DE69433970T2 (de) | 1993-08-10 | 2005-08-11 | W.L. Gore & Associates, Inc., Newark | Zelleinkapselungsvorrichtung |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5626561A (en) | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| EP0773753B1 (en) | 1995-06-07 | 2003-10-08 | Gore Hybrid Technologies, Inc. | An implantable containment apparatus for a therapeutical device |
| AU6854696A (en) | 1995-09-22 | 1997-04-09 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| CA2401327C (en) | 2000-03-03 | 2014-05-06 | Valentis, Inc. | Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US20040014645A1 (en) | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
| US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| ES2653570T3 (es) * | 2004-05-27 | 2018-02-07 | The Trustees Of The University Of Pennsylvania | Células presentadoras de antígeno artificiales novedosas y usos de las mismas |
| KR20080086983A (ko) | 2005-12-07 | 2008-09-29 | 제네트로닉스, 인코포레이티드 | 가변 부피의 전기천공 챔버 및 이의 사용 방법 |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CA2809255A1 (en) * | 2010-08-18 | 2012-02-23 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Methods of identifying central memory t cells and obtaining antigen-specific t cell populations |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013169691A1 (en) | 2012-05-07 | 2013-11-14 | Trustees Of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
| WO2014039044A1 (en) * | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
-
2015
- 2015-10-30 KR KR1020177014806A patent/KR102583138B1/ko active Active
- 2015-10-30 WO PCT/US2015/058228 patent/WO2016069993A1/en not_active Ceased
- 2015-10-30 US US15/521,741 patent/US11471487B2/en active Active
- 2015-10-30 CN CN201580071600.XA patent/CN107106609A/zh active Pending
- 2015-10-30 CA CA2966035A patent/CA2966035A1/en active Pending
- 2015-10-30 AU AU2015339106A patent/AU2015339106B2/en active Active
- 2015-10-30 EP EP15855976.5A patent/EP3217989B1/en active Active
- 2015-10-30 ES ES15855976T patent/ES2910227T3/es active Active
- 2015-10-30 JP JP2017523289A patent/JP6884697B2/ja active Active
- 2015-10-30 KR KR1020237032483A patent/KR20230141922A/ko not_active Ceased
-
2022
- 2022-09-14 US US17/932,188 patent/US20230110342A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533707A5 (OSRAM) | ||
| JP2017535261A5 (OSRAM) | ||
| JP2017533706A5 (OSRAM) | ||
| JP2021058196A5 (OSRAM) | ||
| Putnam et al. | Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation | |
| Zhang et al. | Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside | |
| JP2018504910A5 (OSRAM) | ||
| Dianat‐Moghadam et al. | Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells | |
| Moscarelli et al. | The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells | |
| Wang et al. | Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges | |
| MX2023001962A (es) | Composiciones anti-cd28. | |
| JP2018533625A5 (OSRAM) | ||
| JP2019532625A5 (OSRAM) | ||
| WO2018081789A8 (en) | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion | |
| JP2019500894A5 (OSRAM) | ||
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2014533928A5 (OSRAM) | ||
| FI3102609T3 (fi) | Menetelmiä b-solukasvaimien ja muiden syöpien hoidossa käyttökelpoisten autologisten t-solujen ja niiden koostumusten valmistamiseksi | |
| JP2016539929A5 (OSRAM) | ||
| CN118421557A (zh) | 选择性扩增γδT细胞群的方法及其组合物 | |
| JP2018500006A5 (OSRAM) | ||
| EP3105335A1 (en) | Chimeric antigen receptors and methods of making | |
| JP2016520074A5 (OSRAM) | ||
| WO2019204462A3 (en) | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs | |
| JP2018522040A5 (OSRAM) |